FDA expansion for Symdeko in cystic fibrosis by Anna Smith | Jun 24, 2019 | News | 0 The indication is now for pediatric patients ages six years and older with certain genetic mutations. Read More
Vertex secures US approval for Symdeko by Selina McKee | Feb 13, 2018 | News | 0 US regulators have approved Vertex’ Symdeko, a combination of Kalydeco (ivacaftor) and tezacaftor, to treat certain patients with cystic fibrosis (CF). Read More